kabutan

Cuorips Inc.(4894) Summary

4894
TSE Growth
Cuorips Inc.
8,030
JPY
+140
(+1.77%)
Jan 29, 3:12 pm JST
52.44
USD
Jan 29, 1:12 am EST
Result
PTS
outside of trading hours
8,030
Jan 29, 3:11 pm JST
Summary Chart Historical News Financial Result
PER
PBR
12.9
Yield
ー%
Margin Trading Ratio
306.76
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
7,830 JPY 51.13 USD
Previous Close Jan 28
7,890 JPY 51.69 USD
High Jan 29, 11:28 am
8,240 JPY 53.82 USD
Low Jan 29, 9:00 am
7,830 JPY 51.13 USD
Volume
142,900
Trading Value
1.15B JPY 7.49M USD
VWAP
8021.44 JPY 52.39 USD
Minimum Trading Value
803,000 JPY 5,244 USD
Market Cap
0.07T JPY 0.43B USD
Number of Trades
628
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
876
1-Year High Apr 10, 2025
10,530
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 100 689,800 6898.00
Jan 16, 2026 0 716,800
Jan 9, 2026 1,400 686,900 490.64
Dec 26, 2025 200 674,000 3370.00
Dec 19, 2025 0 691,600
Company Profile
Cuorips Inc. specializes in the development and commercialization of iPS cell-derived cardiomyocyte sheets.
Sector
Pharmaceuticals
Cuorips Inc. focuses on the development and commercialization of human iPS cell-derived cardiomyocyte sheets, working towards the practical application of regenerative medicine products. Through collaborative research with Osaka University and partnerships with major pharmaceutical companies, Cuorips has established advanced cell cultivation techniques. The company's products are expected to improve cardiac function and aid recovery from heart failure in patients with severe cardiac conditions. Utilizing its proprietary commercial cell culture and processing facility "CLiC-1", Cuorips also engages in Contract Development and Manufacturing Organization (CDMO) services and cell culture supernatant businesses. The CDMO services include development support and contract manufacturing, providing various cells as raw materials. The cell culture supernatant business effectively utilizes the liquid byproduct from the cell cultivation process. Cuorips aims to realize a wide range of regenerative medicine technologies, including the development of new catheter-based treatments and research on in vivo regeneration factor inducers.